+13.1%
GSK vs FLNC
-69.0%
+82.1%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | FLNC | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +10.2% | -5.2% | +5.4% |
| 7D | +4.9% | -2.1% | +7.0% | +4.8% |
| 30D | +9.9% | -20.8% | +30.7% | +9.0% |
| 3M | +0.2% | -61.3% | +61.5% | -3.1% |
| 6M | +2.3% | -50.9% | +53.2% | +0.5% |
| YTD | +7.1% | -69.4% | +76.4% | +1.4% |
| 1Y | +13.1% | -68.4% | +81.5% | +7.2% |
| All | +13.1% | -69.0% | +82.1% | +7.2% |
Cumulative growth
Daily Returns
Daily percentage return beside FLNC.
Daily Out/Under-Performance
Portfolio return minus FLNC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × FLNC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded FLNC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling